NO应用于新生儿持续性肺动脉高压治疗的研究进展  

Research progress of nitric oxide for treating neonate with persistent pulmonary hypertension

作　　者：蔡冬 霍开明 CAI Dong;HUO Kaiming(Hainan People's Hospital(Hainan Hospital Affiliated to Hainan Medical University),Haikou,Hainan Province,570100;The Second Affiliated Hospital of Hainan Medical University,Haikou)

机构地区：[1]海南省人民医院,海南医学院附属海南医院,海口570100 [2]海南医学院第二附属医院

出　　处：《中国计划生育学杂志》2024年第10期2454-2458,共5页Chinese Journal of Family Planning

基　　金：2020年海南省基础与应用基础研究计划(省自然科学基金)立项项目(820MS147)。

摘　　要：新生儿持续性肺动脉高压(PPHN)是新生儿期常见的危重疾病,死亡率高达20.6%。目前针对PPHN的药物治疗主要以肺血管扩张剂为主,一氧化氮(NO)作为选择性的肺血管扩张剂,成为治疗新生儿PPHN的首选药物,但是NO同样具有一定局限性。本研究主要是针对NO治疗新生儿PPHN的优劣势,以及联合其他药物在治疗新生儿PPHN的临床效果及存在问题进行了研究综述。Neonatal persistent pulmonary hypertension(PPHN)is a common critical disease during the neonatal period,with the mortality rate of 20.6%.At present,the main drug treatment for the neonatal PPHN is the application of the pulmonary vasodilator.Nitric oxide,as a selective pulmonary vasodilator,has been used as the preferred drug for the treatment of the neonatal PPHN,but nitric oxide also has certain limitations.This paper mainly reviews the advantages and disadvantages of NO for treating the neonatal PPHN,as well as the clinical effect and the existing problems of NO combined with other drugs for treating the neonatal PPHN.

关 键 词：新生儿 持续性肺动脉高压 非特异性血管扩张剂 一氧化氮 联合用药 临床效果 

分 类 号：R722.1[医药卫生—儿科]